Amarin Corp. PLC (NASDAQ:AMRN)’s share price reached a new 52-week high during mid-day trading on Monday . The company traded as high as $3.00 and last traded at $2.89, with a volume of 8,227,859 shares changing hands. The stock had previously closed at $2.65.

A number of equities analysts recently issued reports on AMRN shares. Zacks Investment Research upgraded Amarin Corp. PLC from a “sell” rating to a “hold” rating in a report on Tuesday, April 26th. Jefferies Group reiterated a “buy” rating on shares of Amarin Corp. PLC in a report on Tuesday, May 31st. Finally, HC Wainwright reiterated a “buy” rating and issued a $10.00 target price on shares of Amarin Corp. PLC in a report on Monday, May 9th.

The company has a 50-day moving average of $2.21 and a 200-day moving average of $1.77. The company’s market capitalization is $538.86 million.

Amarin Corp. PLC (NASDAQ:AMRN) last posted its quarterly earnings results on Thursday, May 5th. The biopharmaceutical company reported ($0.14) EPS for the quarter, missing the consensus estimate of ($0.11) by $0.03. The company earned $25.30 million during the quarter, compared to analysts’ expectations of $26.77 million. During the same period in the previous year, the company posted ($0.16) earnings per share. The business’s revenue was up 60.4% on a year-over-year basis. On average, equities research analysts anticipate that Amarin Corp. PLC will post ($0.49) earnings per share for the current year.

An institutional investor recently raised its position in Amarin Corp. PLC stock. OppenheimerFunds Inc. increased its stake in shares of Amarin Corp. PLC (NASDAQ:AMRN) by 0.5% during the fourth quarter, according to its most recent disclosure with the SEC. The fund owned 5,323,360 shares of the biopharmaceutical company’s stock after buying an additional 27,090 shares during the period. OppenheimerFunds Inc. owned 2.90% of Amarin Corp. PLC worth $10,061,000 at the end of the most recent reporting period.

Amarin Corporation plc is a biopharmaceutical company with operations in lipid science focused on the commercialization and development of therapeutics for cardiovascular health. The Company’s lead product, Vascepa (icosapent ethyl) capsule, is approved by the United States Food and Drug Administration (FDA) for use as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.